Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

Clinical trial NCT00261612 · UNKNOWN

Trial details

NCT number: NCT00261612
Sponsor: Medical University of Vienna
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, Mantle-Cell

Start date: 2005-01-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.